Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients With Active Ankylosing Spondylitis

NCT01870284 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01870284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01870284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients With Active Ankylosing Spondylitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Withdrawn
Start date
July 31, 2014
Completion date
April 30, 2018
Enrollment
0 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

spondylitis, ankylosing